Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo®) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland

被引：0
|
作者：
Peter Wiesli
Marcus Schories
机构：
[1] FMH Endokrinologie/Diabetologie,
[2] Kantonsspital Frauenfeld,undefined
[3] FMH Endokrinologie/Diabetologie,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Insulin glargine 300 U/mL; Real-world; Switzerland; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2325 / 2334
页数：9
相关论文
共 50 条
  • [21] Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Nave Type 2 Diabetes Adults: RESTORE-2 Real-World Study
    Fadini, Gian Paolo
    Buzzetti, Raffaella
    Nicolucci, Antonio
    Rossi, Maria Chiara
    Larosa, Monica
    Cucinotta, Domenico
    [J]. DIABETES, 2021, 70
  • [22] Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis
    Joshi, Shashank R.
    Singh, Gursharan
    Marwah, Ashwani
    Mittra, Shivani
    Suvarna, Viraj R.
    Athalye, Sandeep N.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1589 - 1606
  • [23] Real-world analysis of percent of patients with type 2 diabetes achieving glycemic goal with insulin glargine
    Misurski, D.
    Schroeder, B.
    Wade, R.
    Quimbo, R.
    Nielsen, L.
    Fabunmi, R.
    Wintle, M.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A18 - A18
  • [24] A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes
    Tibaldi, Joseph
    Hadley-Brown, Martin
    Liebl, Andreas
    Haldrup, Steffen
    Sandberg, Viktor
    Wolden, Michael L.
    Rodbard, Helena W.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 1001 - 1009
  • [25] Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study
    Escalada, Javier
    Bonnet, Fabrice
    Wu, Jasmanda
    Bonnemaire, Mireille
    Gupta, Shaloo
    Cambron-Mellott, Janelle M.
    Nicholls, Charlie
    Mueller-Wieland, Dirk
    [J]. ADVANCES IN THERAPY, 2020, 37 (09) : 3863 - 3877
  • [26] Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study
    Javier Escalada
    Fabrice Bonnet
    Jasmanda Wu
    Mireille Bonnemaire
    Shaloo Gupta
    Janelle M. Cambron-Mellott
    Charlie Nicholls
    Dirk Müller-Wieland
    [J]. Advances in Therapy, 2020, 37 : 3863 - 3877
  • [27] CONFIRM: a comparative effectiveness study of insulin degludec and insulin glargine 300 units/ ml (glargine U300) in insulin-naive patients with type 2 diabetes
    Tibaldi, J.
    Haldrup, S.
    Sandberg, V.
    Wolden, M. L.
    Rodbard, H. W.
    [J]. DIABETOLOGIA, 2018, 61 : S44 - S44
  • [28] GLYCEMIC CONTROL AND HYPOGLYCEMIA WITH NEW INSULIN GLARGINE 300 U/ML IN PEOPLE WITH TYPE 1 DIABETES (EDITION 4)
    Home, P. D.
    Bergenstal, R.
    Riddle, M. C.
    Rojeski, M.
    Espinasse, M.
    Bolli, G. B.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A104 - A105
  • [29] Real-World Titration of Insulin Glargine 100 U/mL in Patients with Type 2 Diabetes Poorly Controlled on Oral Antidiabetic Drugs
    Seufert, Jochen
    Anderten, Helmut
    Borck, Anja
    Fritsche, Andreas
    Pegelow, Katrin
    Pscherer, Stefan
    [J]. DIABETES, 2017, 66 : A619 - A619
  • [30] Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus
    Freemantle, Nick
    Mauricio, Didac
    Giaccari, Andrea
    Bailey, Timothy
    Roussel, Ronan
    Franco, Denise
    Berthou, Baptiste
    Pilorget, Valerie
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Bonnemaire, Mireille
    Cali, Anna M. G.
    Nguyen-Pascal, My-Lien
    Penfornis, Alfred
    Perez-Maraver, Manuel
    Seufert, Jochen
    Sullivan, Sean D.
    Wilding, John
    Wysham, Carol
    Davies, Melanie
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (04) : 571 - 581
12345